{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:59:46Z","timestamp":1784563186679,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01NS097197"],"award-info":[{"award-number":["P01NS097197"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taysha Gene Therapies"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01218-7","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:31:38Z","timestamp":1648513898000},"page":"982-993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models"],"prefix":"10.1016","volume":"19","author":[{"given":"Emrah","family":"Gumusgoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahba","family":"Kasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikran R.","family":"Guisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Verhalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1007\/s13311-022-01218-7_bib1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ana.410440604","article-title":"Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene","volume":"44","author":"Lossos","year":"1998","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01218-7_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaneurol.2014.4496","article-title":"Deep intronic GBE1 mutation in manifesting heterozygous patients with adult polyglucosan body disease","volume":"72","author":"Akman","year":"2015","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01218-7_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1566524024605761","article-title":"Glycogen and its metabolism","volume":"2","author":"Roach","year":"2002","journal-title":"Curr Mol Med"},{"key":"10.1007\/s13311-022-01218-7_bib4","doi-asserted-by":"crossref","unstructured":"Sullivan MA, Nitschke S, Skwara EP, et al. Skeletal muscle glycogen chain length correlates with insolubility in mouse models of polyglucosan-associated neurodegenerative diseases. Cell Rep. 2019;27(5):1334\u201344 e6.","DOI":"10.1016\/j.celrep.2019.04.017"},{"issue":"2","key":"10.1007\/s13311-022-01218-7_bib5","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s13311-021-01040-7","article-title":"Targeting Gys1 with AAV-SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and Lafora disease mouse models","volume":"18","author":"Gumusgoz","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1007\/s13311-022-01218-7_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/brain\/103.2.315","volume":"103","author":"Robitaille","year":"1980","journal-title":"Brain"},{"issue":"2","key":"10.1007\/s13311-022-01218-7_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"10.1007\/s13311-022-01218-7_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet"},{"issue":"10","key":"10.1007\/s13311-022-01218-7_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01218-7_bib10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s12035-019-01842-z","article-title":"Reactive glia-derived neuroinflammation: a novel hallmark in Lafora progressive myoclonus epilepsy that progresses with age","volume":"57","author":"Lahuerta","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"6","key":"10.1007\/s13311-022-01218-7_bib11","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s00259-019-04647-3","article-title":"FDG-PET assessment and metabolic patterns in Lafora disease","volume":"47","author":"Muccioli","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s13311-022-01218-7_bib12","unstructured":"Van Heycop Ten Ham MW. Lafora disease, a form of progressive myoclonus epilepsy In: Magnus O, and Lorentz de Haas, A. M. eds., editor. The epilepsies handbook of clinical neurology 15. Amsterdam, New York: North-Holland Publishing Elsevier; 1974. p. 382\u2013422."},{"key":"10.1007\/s13311-022-01218-7_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02863929","article-title":"Beitrag zur histpathologie der myoklonischen Epilepsie","volume":"6","author":"Lafora","year":"1911","journal-title":"Z Ges Neurol Psychiat"},{"key":"10.1007\/s13311-022-01218-7_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-6606-7-7","article-title":"Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease","volume":"7","author":"Ortolano","year":"2014","journal-title":"Mol Brain"},{"issue":"11","key":"10.1007\/s13311-022-01218-7_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/emmm.201100174","article-title":"Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease","volume":"3","author":"Valles-Ortega","year":"2011","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1007\/s13311-022-01218-7_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pederson","year":"2013","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1007\/s13311-022-01218-7_bib17","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-022-01218-7_bib18","doi-asserted-by":"crossref","unstructured":"Varea O, Duran J, Aguilera M, et al. Suppression of glycogen synthesis as a treatment for Lafora disease: establishing the window of opportunity. Neurobiol Dis. 2021;147:105173.","DOI":"10.1016\/j.nbd.2020.105173"},{"issue":"11","key":"10.1007\/s13311-022-01218-7_bib19","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/acn3.51211","article-title":"GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease","volume":"7","author":"Chown","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1007\/s13311-022-01218-7_bib20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/jnc.15176","article-title":"Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease","volume":"157","author":"Israelian","year":"2021","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01218-7_bib21","doi-asserted-by":"crossref","unstructured":"Nitschke S, Chown EE, Zhao X, et al. An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice. J Biol Chem. 2021;296:100150.","DOI":"10.1074\/jbc.RA120.015773"},{"key":"10.1007\/s13311-022-01218-7_bib22","doi-asserted-by":"crossref","unstructured":"Turnbull J, DePaoli-Roach AA, Zhao X, et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet. 2011;7(4):e1002037.","DOI":"10.1371\/journal.pgen.1002037"},{"issue":"3","key":"10.1007\/s13311-022-01218-7_bib23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01218-7_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awab194","article-title":"Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease","author":"Ahonen","year":"2021","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01218-7_bib25","doi-asserted-by":"crossref","unstructured":"Boudreau RL, Spengler RM, Hylock RH, et al. siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res. 2013;41(1):e9.","DOI":"10.1093\/nar\/gks797"},{"key":"10.1007\/s13311-022-01218-7_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/B978-0-12-386509-0.00014-4","article-title":"Generation of hairpin-based RNAi vectors for biological and therapeutic application","volume":"507","author":"Boudreau","year":"2012","journal-title":"Methods Enzymol"},{"issue":"9","key":"10.1007\/s13311-022-01218-7_bib27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1007\/s13311-022-01218-7_bib28","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Clement","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1007\/s13311-022-01218-7_bib29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","article-title":"Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice","volume":"11","author":"Ganesh","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1007\/s13311-022-01218-7_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.22156","article-title":"Glycogen hyperphosphorylation underlies lafora body formation","volume":"68","author":"Turnbull","year":"2010","journal-title":"Ann Neurol"},{"issue":"23","key":"10.1007\/s13311-022-01218-7_bib31","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1093\/hmg\/ddv385","article-title":"A novel mouse model that recapitulates adult-onset glycogenosis type 4","volume":"24","author":"Orhan Akman","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-022-01218-7_bib32","doi-asserted-by":"crossref","unstructured":"Kawasaki H, Kosugi I, Sakao-Suzuki M, et al. Intracerebroventricular and intravascular injection of viral particles and fluorescent microbeads into the neonatal brain. J Vis Exp. 2016(113).","DOI":"10.3791\/54164-v"},{"issue":"43","key":"10.1007\/s13311-022-01218-7_bib33","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1074\/jbc.RA120.015061","article-title":"Sensitive quantification of alpha-glucans in mouse tissues, cell cultures, and human cerebrospinal fluid","volume":"295","author":"Nitschke","year":"2020","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1007\/s13311-022-01218-7_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/mt.2008.231","article-title":"Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-022-01218-7_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4939-3271-9_5","article-title":"Design of shRNA and miRNA for delivery to the CNS","volume":"1382","author":"Toro Cabrera","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1007\/s13311-022-01218-7_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12325","article-title":"GBE1-related disorders: adult polyglucosan body disease and its neuromuscular phenotypes","volume":"44","author":"Souza","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"10.1007\/s13311-022-01218-7_bib37","article-title":"Lafora disease: current biology and therapeutic approaches","author":"Mitra","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1007\/s13311-022-01218-7_bib38","doi-asserted-by":"crossref","unstructured":"Sullivan MA, Nitschke S, Steup M, et al. Pathogenesis of Lafora disease: transition of soluble glycogen to insoluble polyglucosan. Int J Mol Sci. 2017;18(8).","DOI":"10.3390\/ijms18081743"},{"key":"10.1007\/s13311-022-01218-7_bib39","doi-asserted-by":"crossref","unstructured":"Sanz P, Serratosa JM. Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities. Expert Rev Mol Med. 2020;22:e4.","DOI":"10.1017\/erm.2020.5"},{"issue":"5","key":"10.1007\/s13311-022-01218-7_bib40","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s12035-016-9884-4","article-title":"Inflammation in Lafora disease: evolution with disease progression in Laforin and Malin knock-out mouse models","volume":"54","author":"Lopez-Gonzalez","year":"2017","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10.1007\/s13311-022-01218-7_bib41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s12035-020-02170-3","article-title":"Trehalose ameliorates seizure susceptibility in Lafora disease mouse models by suppressing neuroinflammation and endoplasmic reticulum stress","volume":"58","author":"Sinha","year":"2021","journal-title":"Mol Neurobiol"},{"issue":"7","key":"10.1007\/s13311-022-01218-7_bib42","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1021\/acs.jmedchem.9b01851","article-title":"Discovery and development of small-molecule inhibitors of glycogen synthase","volume":"63","author":"Tang","year":"2020","journal-title":"J Med Chem"},{"issue":"24","key":"10.1007\/s13311-022-01218-7_bib43","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1016\/j.febslet.2009.10.036","article-title":"Correlation of mRNA and protein in complex biological samples","volume":"583","author":"Maier","year":"2009","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1007\/s13311-022-01218-7_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13023-021-01989-w","article-title":"Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis","volume":"16","author":"Pondrelli","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1007\/s13311-022-01218-7_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ana.23598","article-title":"Adult polyglucosan body disease: natural history and key magnetic resonance imaging findings","volume":"72","author":"Mochel","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01218-7_bib46","unstructured":"Natural History and Functional Status Study of Patients With Lafora Disease. clinicaltrials.gov # NCT03876522. 2022."},{"issue":"5","key":"10.1007\/s13311-022-01218-7_bib47","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/jimd.12234","article-title":"RBCK1-related disease: a rare multisystem disorder with polyglucosan storage, auto-inflammation, recurrent infections, skeletal, and cardiac myopathy-four additional patients and a review of the current literature","volume":"43","author":"Phadke","year":"2020","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1007\/s13311-022-01218-7_bib48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ana.23963","article-title":"Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1","volume":"74","author":"Nilsson","year":"2013","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01218-7_bib49","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/hmg\/ddz032","article-title":"Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24","volume":"28","author":"Hedberg-Oldfors","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1007\/s13311-022-01218-7_bib50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41419-019-1488-2","article-title":"RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma","volume":"10","author":"Yu","year":"2019","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1007\/s13311-022-01218-7_bib51","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ng.3701","article-title":"Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility","volume":"48","author":"Lin","year":"2016","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-022-01218-7_bib52","doi-asserted-by":"crossref","unstructured":"Kelsall IR, McCrory EH, Xu Y, et al. HOIL-1-catalysed ubiquitylation of unbranched glucosaccharides and its activation by ubiquitin oligomers. bioRxiv. 2021:2021.09.10.459791.","DOI":"10.1101\/2021.09.10.459791"},{"issue":"5","key":"10.1007\/s13311-022-01218-7_bib53","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1042\/BST20210838","article-title":"LUBAC: a new player in polyglucosan body disease","volume":"49","author":"Aboujaoude","year":"2021","journal-title":"Biochem Soc Trans"},{"key":"10.1007\/s13311-022-01218-7_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awac017","article-title":"Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency","author":"Nitschke","year":"2022","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01218-7_bib55","doi-asserted-by":"crossref","unstructured":"Clayton NP, Nelson CA, Weeden T, et al. Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease. Mol Ther Nucleic Acids. 2014;3:e206.","DOI":"10.1038\/mtna.2014.57"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01218-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:56:20Z","timestamp":1761807380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011170"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01218-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01218-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}